PR Newswire · Press release
Insmed to Present at November and December 2026 Investor Conferences
AI summary
Summary by Wenlo · not part of the original release
Insmed Incorporated announced that management will present at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026, at 2:00 p.m. GT / 9:00 a.m. ET. Management will also present at the Evercore 9th Annual Healthcare Conference in Coral Gables, Florida, on Tuesday, December 1, 2026, at 9:10 a.m. ET. Live webcasts of these events will be available on the company website and archived for 30 days.
AI summaries can miss details: read the full release below. Not investment advice.
Original release from PR Newswire
As distributed by PR Newswire, unedited.
BRIDGEWATER, N.J., Nov. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:
- Jefferies Global Healthcare Conference in London on Monday, November 16, 2026, at 2:00 p.m. GT / 9:00 a.m. ET.
- Evercore 9th Annual Healthcare Conference in Coral Gables, Florida, on Tuesday, December 1, 2026, at 9:10 a.m. ET.
These events will be webcasted live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.
Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.
Contact:
Investors:
Gianna De Palma
Associate Director, Investor Relations
investor.relations@insmed.com
Media:
Claire Mulhearn
Vice President, Corporate Communications
media@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-november-and-december-2026-investor-conferences-302926989.html
SOURCE Insmed Incorporated
